Table 2.

Treatment and outcomes of published HCCC cases by location

Location	Exc (%)	Exc and LND (%)	Exc, LND, and RT (%)	Exc and RT (%)	RT only (%)	Exc and ChemoRT (%)	Othera (%)	Follow-up range (months)	NED (%)	Recurrence (%)
BOT	58	10	8	5	3	3	3	3–124	65	18
Bronchus	50	50	0	0	0	0	0	10–181	100	0
Buccal/cheek	73	9	0	18	0	0	0	5–132	64	27
FOM	67	13	20	0	0	0	0	2.5–108	73	7
Gingiva	50	50	0	0	0	0	0	12–31	100	0
Hypopharynx	0	50	0	0	0	0	0	62	100	0
Larynx	67	0	0	33	0	0	0	24–55	100	0
Lip	100	0	0	0	0	0	0	2–73	100	0
Mandible	71	29	0	0	0	0	0	3–78	71	29
Maxilla	46	7	7	7	0	0	0	3–36	38	23
Nasal cavity	50	0	0	50	0	0	0	7	0	50
Nasopharynx	50	0	8	25	0	0	1	2.5–144	58	8
Neck	–	100	0	0	0	0	0	–	–	–
Oral	100	0	0	0	0	0	0	–	–	0
Orbit/lacrimal gland	100	0	0	0	0	0	0	–	100	0
Oropharynx	80	0	0	0	0	20	0	12–81	60	20
Palate	67	2	7	10	0	0	3	6–348	60	19
Paranasal sinus	34	0	0	67	0	0	0	4–9	67	0
Parotid	100	0	0	0	0	0	0	1–195	55	18
Sinonasal tract	–	–	–	–	–	–	–	48	100	0
Sublingual	100	–	–	–	–	–	–	12	100	–
Submandibular	–	–	–	–	–	–	–	–	100	0
Thymus	–	–	–	–	–	–	–	–	–	–
Tongue	67	8	0	17	0	0	8	8–132	42	8
Tonsil	80	0	0	20	0	0	0	4–72	40	20
Trachea	0	33	33	33	0	0	33	12–52	67	0

BOT base of tongue, FOM floor of mouth, Exc excision, LND lymph node dissection, RT radiotherapy, ChemoRT chemoradiotherapy, NED no evidence of disease

^aOther; includes no treatment or debulking for unresectable tumors